Dr. Umme Sabrina Haque is a PhD candidate in the Yokota Lab within the Neuroscience and Mental Health Institute at the University of Alberta, Faculty of Medicine & Dentistry. Her research focuses on developing antisense oligonucleotide (ASO) and CRISPR/Cas‑based therapeutic strategies for neuromuscular diseases, including spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and giant axonal neuropathy. A key aim of her work is to design safe, non‑invasive delivery approaches capable of achieving therapeutic rescue across the central nervous system and multiple organ systems.

She is driven by research and innovation and has authored and co‑authored several peer‑reviewed publications in the field. Prior to beginning her doctoral studies, her master’s research applied genome‑editing technologies to develop salt‑tolerant, high‑yield rice varieties to address food security challenges in Bangladesh.

Haque brings more than three years of experience as a Junior Scientific Officer, Molecular Biologist, and Research Assistant, and has been recognized with multiple competitive awards.

In 2026, she began serving as a Basic Science Trainee Committee member within the NMD4C, contributing to the development of Pre-Clinical Science Standard Operating Procedures (SOPs).